Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease

Excessive inflammation seems important in chronic obstructive pulmonary disease (COPD), particularly during exacerbations of the disease. Exhaled nitric oxide concentration ([NOexh]) is a sensitive marker of bronchial inflammation in asthma; it is unclear if this is also the case in COPD. This study: 1) quantifies [NOexh] in patients with COPD (during an exacerbation and while clinically stable); 2) investigates the response of [NOexh] to i.v. steroid therapy, and its potential relationship with other relevant physiological variables; and 3) assesses the relative contributions of the central and peripheral airways to [NOexh] by collecting exhaled air in two different bags connected in series. Seventeen COPD patients (forced expiratory volume in one second (FEV1) 37.6+/-3.4% of the predicted value (+/-SEM)) hospitalized because of an exacerbation of the disease (arterial oxygen tension (Pa,O2) (7.46+/-0.72 kPa 56.1+/-5.4 mmHg), arterial carbon dioxide tension (Pa,CO2) 5.63+/-0.37 kPa 42.3+/-2.8 mmHg), pH 7.41+/-0.02) and 10 healthy subjects that served as controls were studied. On admission, [NOexh] in COPD was higher than normal (41.0+/-5.1 versus 13.3+/-0.8 parts per billion (ppb), respectively, p<0.001). Despite i.v. steroid therapy, [NOexh] remained elevated throughout recovery (37.9+/-4.8 ppb, p<0.001) until discharge (40.9+/-4.3 ppb, p<0.001). In contrast, when the patients were clinically stable (several months later), [NOexh] was significantly reduced (15.8+/-3.8 ppb, p<0.001), and no longer different from control values. [NOexh] was not related to any of the physiological variables measured during recovery (pulmonary gas exchange) or at discharge (forced spirometry, lung volumes, diffusing capacity). Finally, the contribution of the central and peripheral airways to [NOexh] was not different at any point in time. These results indicate that during exacerbations of chronic obstructive pulmonary disease, the exhaled nitric oxide concentration: 1) is higher than normal; 2) is not reduced acutely by i.v. steroids but is normalized several months after discharge; 3) is unrelated to several physiological indices of disease severity; and 4) appears to be produced homogeneously in central and peripheral airways. Overall, these results are different from those reported in asthma, suggesting that different inflammatory mechanisms are operating in both diseases.

This article has been cited by other articles:

				K. G. Lim and C. Mottram The Use of Fraction of Exhaled Nitric Oxide in Pulmonary Practice Chest, May 1, 2008; 133(5): 1232 - 1242. [Abstract] [Full Text] [PDF]

				M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]

				B. R. Celli and P. J. Barnes Exacerbations of chronic obstructive pulmonary disease Eur. Respir. J., June 1, 2007; 29(6): 1224 - 1238. [Abstract] [Full Text] [PDF]

				D R Taylor, M W Pijnenburg, A D Smith, and J C D Jongste Exhaled nitric oxide measurements: clinical application and interpretation Thorax, September 1, 2006; 61(9): 817 - 827. [Abstract] [Full Text] [PDF]

				P. J. Barnes, B. Chowdhury, S. A. Kharitonov, H. Magnussen, C. P. Page, D. Postma, and M. Saetta Pulmonary Biomarkers in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 6 - 14. [Abstract] [Full Text] [PDF]

				J. Vestbo Clinical Assessment, Staging, and Epidemiology of Chronic Obstructive Pulmonary Disease Exacerbations Proceedings of the ATS, May 1, 2006; 3(3): 252 - 256. [Abstract] [Full Text] [PDF]

				J. Choi, L. A. Hoffman, G. W. Rodway, and J. M. Sethi Markers of lung disease in exhaled breath: nitric oxide. Biol Res Nurs, April 1, 2006; 7(4): 241 - 255. [Abstract] [PDF]

				A. Bhowmik, T. A. R. Seemungal, G. C. Donaldson, and J. A. Wedzicha Effects of exacerbations and seasonality on exhaled nitric oxide in COPD Eur. Respir. J., December 1, 2005; 26(6): 1009 - 1015. [Abstract] [Full Text] [PDF]

				M. Tsoumakidou, N. Tzanakis, G. Chrysofakis, and N. M. Siafakas Nitrosative Stress, Heme Oxygenase-1 Expression and Airway Inflammation During Severe Exacerbations of COPD Chest, June 1, 2005; 127(6): 1911 - 1918. [Abstract] [Full Text] [PDF]

				P. J. Barnes Mediators of Chronic Obstructive Pulmonary Disease Pharmacol. Rev., December 1, 2004; 56(4): 515 - 548. [Abstract] [Full Text] [PDF]

				F. L. M. Ricciardolo, P. J. Sterk, B. Gaston, and G. Folkerts Nitric Oxide in Health and Disease of the Respiratory System Physiol Rev, July 1, 2004; 84(3): 731 - 765. [Abstract] [Full Text] [PDF]

				T. J. Toward, N. Smith, and K. J. Broadley Effect of Phosphodiesterase-5 Inhibitor, Sildenafil (Viagra), in Animal Models of Airways Disease Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 227 - 234. [Abstract] [Full Text] [PDF]

				P.J. Barnes, S.D. Shapiro, and R.A. Pauwels Chronic obstructive pulmonary disease: molecular and cellularmechanisms Eur. Respir. J., October 1, 2003; 22(4): 672 - 688. [Abstract] [Full Text] [PDF]

				F L M Ricciardolo Multiple roles of nitric oxide in the airways Thorax, February 1, 2003; 58(2): 175 - 182. [Abstract] [Full Text] [PDF]

				M. Miravitlles Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur. Respir. J., July 1, 2002; 20(36_suppl): 9S - 19s. [Abstract] [Full Text] [PDF]

				C. Sohy, C. Pilette, M.S. Niederman, and Y. Sibille Acute exacerbation of chronic obstructive pulmonary disease and antibiotics: what studies are still needed? Eur. Respir. J., May 1, 2002; 19(5): 966 - 975. [Abstract] [Full Text] [PDF]

				I. M. FERREIRA, M. S. HAZARI, C. GUTIERREZ, N. ZAMEL, and K. R. CHAPMAN Exhaled Nitric Oxide and Hydrogen Peroxide in Patients with Chronic Obstructive Pulmonary Disease . Effects of Inhaled Beclomethasone Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 1012 - 1015. [Abstract] [Full Text] [PDF]

				T. J. Toward and K. J. Broadley Chronic Lipopolysaccharide Exposure on Airway Function, Cell Infiltration, and Nitric Oxide Generation in Conscious Guinea Pigs: Effect of Rolipram and Dexamethasone J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 298 - 306. [Abstract] [Full Text]

				E Clini, L Bianchi, K Foglio, R Porta, M Vitacca, and N Ambrosino Effect of pulmonary rehabilitation on exhaled nitric oxide in patients with chronic obstructive pulmonary disease Thorax, July 1, 2001; 56(7): 519 - 523. [Abstract] [Full Text] [PDF]

				R. Wilson Bacteria, antibiotics and COPD Eur. Respir. J., May 1, 2001; 17(5): 995 - 1007. [Abstract] [Full Text] [PDF]

				P. E. Silkoff, D. Martin, J. Pak, J. Y. Westcott, and R. J. Martin Exhaled Nitric Oxide Correlated With Induced Sputum Findings in COPD Chest, April 1, 2001; 119(4): 1049 - 1055. [Abstract] [Full Text] [PDF]

				P. J. Barnes Chronic Obstructive Pulmonary Disease N. Engl. J. Med., July 27, 2000; 343(4): 269 - 280. [Full Text] [PDF]